Jayanthi S Lea

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint Cervical cancer
    Jayanthi S Lea
    University of Texas Southwestern School of Medicine, Dallas, TX 75390 9032, USA
    Obstet Gynecol Clin North Am 39:233-53. 2012
  2. ncbi request reprint Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells
    Jayanthi S Lea
    Division ofGynecologic Oncology, Hamon Center of Therapeutic Oncology Research, University ofTexas Southwestern Medical Center, Dallas, TX75390 9032, USA
    Reprod Sci 14:20-8. 2007
  3. ncbi request reprint Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Obstet Gynecol 190:674-9. 2004
  4. ncbi request reprint Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9032, USA
    Gynecol Oncol 91:558-62. 2003
  5. ncbi request reprint Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    J Soc Gynecol Investig 11:329-37. 2004
  6. ncbi request reprint Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ
    Jayanthi S Lea
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    Gynecol Oncol 87:129-32. 2002
  7. ncbi request reprint Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75390, USA
    Am J Obstet Gynecol 188:640-4. 2003
  8. ncbi request reprint Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390 9032, USA
    J Reprod Med 48:751-5. 2003
  9. ncbi request reprint Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection
    Jayanthi S Lea
    Division of Gynecologic Oncology, University of Texas Southwestern, Dallas, Texas 75390, USA
    Gynecol Oncol 84:285-8. 2002
  10. ncbi request reprint Adenocarcinoma of the cervix
    John O Schorge
    Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390, USA
    Curr Treat Options Oncol 5:119-27. 2004

Collaborators

Detail Information

Publications16

  1. doi request reprint Cervical cancer
    Jayanthi S Lea
    University of Texas Southwestern School of Medicine, Dallas, TX 75390 9032, USA
    Obstet Gynecol Clin North Am 39:233-53. 2012
    ..Improvements in radiation techniques and molecular targeted therapy are the current research venues in cervical cancer...
  2. ncbi request reprint Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells
    Jayanthi S Lea
    Division ofGynecologic Oncology, Hamon Center of Therapeutic Oncology Research, University ofTexas Southwestern Medical Center, Dallas, TX75390 9032, USA
    Reprod Sci 14:20-8. 2007
    ..RNA interference targeting the E7 portion of the bicistronic HPV 18 mRNA can silence both E6 and E7 oncoproteins and is most effective in cervical cancer growth inhibition...
  3. ncbi request reprint Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Obstet Gynecol 190:674-9. 2004
    ..The purpose of this study was to determine the association between active tobacco exposure and aberrant p16 promoter methylation in primary cervical squamous cell cancer and high-grade squamous cervical dysplasia...
  4. ncbi request reprint Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9032, USA
    Gynecol Oncol 91:558-62. 2003
    ..The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 cervical adenocarcinoma..
  5. ncbi request reprint Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    J Soc Gynecol Investig 11:329-37. 2004
    ..The goal of this study was to confirm the utility of homozygous deletions, aberrant methylation, and immunohistochemical evaluations of FHIT as functionally relevant determinants of FHIT expression...
  6. ncbi request reprint Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ
    Jayanthi S Lea
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    Gynecol Oncol 87:129-32. 2002
    ..To determine if performing an endocervical curettage (ECC) at the time of conization is a useful diagnostic tool for predicting residual cervical adenocarcinoma in situ (AIS) among women who might wish to preserve their fertility...
  7. ncbi request reprint Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75390, USA
    Am J Obstet Gynecol 188:640-4. 2003
    ..We compared the clinical outcome of cervical adenocarcinoma in Hispanic and white women to determine whether race was an independent predictor of survival...
  8. ncbi request reprint Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390 9032, USA
    J Reprod Med 48:751-5. 2003
    ..To conduct a surveillance trial after conization to prospectively determine the outcome of conservative management of adenocarcinoma in situ (AIS)...
  9. ncbi request reprint Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection
    Jayanthi S Lea
    Division of Gynecologic Oncology, University of Texas Southwestern, Dallas, Texas 75390, USA
    Gynecol Oncol 84:285-8. 2002
    ..The purpose of this study was to further define the node of para-aortic lymph node dissection in early-stage cervical adenocarcinoma treated by surgical intent...
  10. ncbi request reprint Adenocarcinoma of the cervix
    John O Schorge
    Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390, USA
    Curr Treat Options Oncol 5:119-27. 2004
    ..Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy...
  11. ncbi request reprint P16 as a molecular biomarker of cervical adenocarcinoma
    John O Schorge
    Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Tex, USA
    Am J Obstet Gynecol 190:668-73. 2004
    ..Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection...
  12. doi request reprint Implications of EGFR inhibition in ovarian cancer cell proliferation
    Shawna L Bull Phelps
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Gynecol Oncol 109:411-7. 2008
    ..Targeted inhibition of EGFR via its tyrosine kinase domain is a successful treatment in lung cancer. Our objective was to correlate EGFR over-expression and growth inhibition, by EGF receptor inhibitors, in ovarian cancer...
  13. ncbi request reprint Management of low-risk gestational trophoblastic neoplasia in indigent women
    John O Schorge
    Southwestern Trophoblastic Disease Center, Division of Gynecologic Oncology, Dep of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, 75390 9032, USA
    J Reprod Med 48:780-4. 2003
    ..To identify the most effective dosing regimen for indigent patients with low-risk gestational trophoblastic neoplasia (GTN) at high risk of noncompliance...
  14. pmc Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity
    Shawna L Bull Phelps
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8593, USA
    Am J Obstet Gynecol 200:180.e1-7. 2009
    ..Secreted protein acidic and rich in cysteine (SPARC) influences the growth of several solid tumors. Our objectives were to determine the effect of SPARC on the growth and response to cisplatin therapy of platinum-resistant ovarian cancer...
  15. doi request reprint Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer
    John O Schorge
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Int J Gynaecol Obstet 108:123-7. 2010
    ..To determine the risks and benefits of secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer...
  16. ncbi request reprint Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival
    Jayanthi S Lea
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Gynecol Oncol 84:115-9. 2002
    ..Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease...